Table 1.

Global prevalence of chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection. Chronic HBV infection was defined as HBsAg seroprevalence. Prevalence data for chronic HBV was generated from a systematic review for the GBD, representing 161 countries and study population of over 119 million individuals (20). HCV was defined as anti-HCV seroprevalence. Prevalence data for HCV infection was generated from a review for the GBD on changing HCV prevalence (24).

	HBsAg Prevalence				Anti-HCV Prevalence
	Low <2.0%	Lower intermediate 2.0–4.99%	Higher intermediate 5.0–7.99%	High ≥8.0%	Low <1.5%	Intermediate 1.5–3.5%	High >3.5%
High-income
High-income Australasia		2.2 (1.4–4.1)				2.7 (2.2–3.2)
High-income Asia Pacific		3.4 (1.8–5.0)			1.4 (1.2–1.5)
High-income North America	0.5 (0.3–0.8)				1.3 (1.1–1.6)
High-income Southern Latin America	0.7 (0.6–0.8%)					1.6 (1.1–2.2)
Western Europe	0.8 (0.4–1.1)					2.4 (2.2–2.7)
Central Europe, Eastern Europe, Central Asia
Central Asia			6.4 (4.3–8.6)				3.8 (3.0–4.5)
Central Europe		2.2 (0.7–3.7)				2.4 (2.0–2.8)
Eastern Europe		3.6 (1.4–5.7)				2.9 (2.3–3.5)
South Asia
South Asia		2.6 (1.2–4.0)				3.4 (2.6–4.4)
Southeast Asia, East Asia and Oceania
East Asia			5.5				3.7 (3.1–4.5)
Southeast Asia		4.4 (2.2–6.5)				2.0 (1.7–2.3)
Oceania				12.8 (7.8–18.7)		2.3 (2.1–3.1)
Latin America and Caribbean
Andean Latin America	1.5 (0.4–2.6)					2.0 (1.4–2.7)
Caribbean		4.7 (1.6–7.7)				2.1 (1.6–2.6)
Central Latin America	0.9 (0.3–1.5)					1.6 (1.3–1.9)
Tropical Latin America	0.7				1.2 (1.0–1.4)
North Africa and Middle East
North Africa and Middle East		2.6 (1.6–3.6)					3.6 (3.2–4.1)
Sub-Saharan Africa
Central Sub-Saharan Africa				10.6 (8.4–12.8)		2.3 (1.6–3.1)
East Sub-Saharan Africa				9.0 (6.5–11.4)		2.0 (1.6–2.4)
South Sub-Saharan Africa				12.2 (6.7–17.7)		2.1 (1.7–2.5)
Western Sub-Saharan Africa				12.4 (11.0–13.9)		2.8 (2.4–3.3)